Early post-discharge mortality in CAP: frequency, risk factors and a prediction tool

Verena Glöckner¹ · Mathias W. Pletz²,8 · Gernot Rohde³,8,9 · Jan Rupp⁴,5,8 · Martin Witzenrath⁶,8,9 · Grit Barten-Neiner⁷,8 · Martin Kolditz¹ · for the CAPNETZ Study Group

Abstract
There are few data on mortality after discharge with community-acquired pneumonia (CAP). Therefore, we evaluated risk factors for 30-day post-discharge mortality after CAP. We included all patients of the prospective multi-national CAPNETZ study between 2002 and 2018 with (1) hospitalized CAP, (2) survival until discharge, and (3) complete follow-up data. The study endpoint was death within 30 days after discharge. We evaluated risk factors including demographics, comorbidities, admission CAP severity, and laboratory values and treatment-related factors in uni- and multivariable analyses. A total of 126 (1.6%) of 7882 included patients died until day 30 after discharge, corresponding to 26% of all 476 deaths. After multivariable analysis, we identified 10 independent risk factors: higher age, lower BMI, presence of diabetes mellitus, chronic renal or chronic neurological disease (other than cerebrovascular diseases), low body temperature or higher thrombocytes on admission, extended length of hospitalization, oxygen therapy during hospitalization, and post-obstructive pneumonia. By addition these factors, we calculated a risk score with an AUC of 0.831 (95%CI 0.822–0.839, \( p < 0.001 \)) for prediction of post-discharge mortality. Early post-discharge deaths account for \( \frac{1}{4} \) of all CAP-associated deaths and are associated with patient- and CAP-severity-related risk factors. Additional studies are necessary to replicate our findings in independent cohorts. Study registration: NCT 02139163.

Keywords Community-acquired pneumonia · Prognosis · Post-discharge · Mortality

Introduction
Complications and short- or long-term mortality after hospital discharge because of community-acquired pneumonia (CAP) contribute significantly to the burden of this disease [1]. Whereas long-term mortality after CAP is predominantly comorbidity-related [2, 3], early (within 30 days) post-discharge complications might have potential for CAP-related causes susceptible to specific interventions. Recent population-based German data demonstrated a high mortality increase of 4.7% between in-hospital mortality (17.2%) and 30-day mortality (21.9%) in a cohort of 16,274 hospitalized patients with CAP [4]. A study from the USA (\( n = 3,000,000 \) 2005–2015) also showed an alarmingly high...
30-day post-discharge mortality of 8.2% for patients with pneumonia [5]. Other recent studies identified 30-day post-discharge mortality rates between 3 and 6% [6–10]. However, from large multicenter cohorts, there are very few data regarding risk factors for early post-discharge complications or mortality of patients that were hospitalized with CAP [7]. Accordingly, recent international guidelines on management of CAP provide almost no evidence-based recommendations for post-hospital care [11, 12]. In order to identify, initiate, and tailor optimized patient follow-up and structured discharge interventions to improve post-discharge prognosis, data on specific risk factors are necessary. Therefore, the present study aimed to evaluate risk factors for early (within 30 days) post-discharge mortality in patients surviving hospitalization because of CAP from the CAPNETZ cohort.

Methods

Study cohort

Since 2001, the multi-national prospective CAPNETZ study (study registration NCT 02139,163) prospectively collects data an biosamples on patients with CAP in more than 40 local clinical centers in central Europe (https://www.capnetz.de/html/capnetz/lccs). A detailed description of the CAPNETZ methodology is given elsewhere [13]. Criteria for inclusion in CAPNETZ are age ≥ 18 years, a pulmonary infiltrate diagnosed by chest imaging, and at least one of the following criteria: history of fever (temperature ≥ 38.3 °C), cough, production of purulent sputum, or focal chest signs on auscultation. Exclusion criteria are acquired or therapeutically induced immune deficiency, active TB, or nosocomial acquisition of infection. All patients are followed up according to a standardized protocol for 180 days and all clinical parameters are stored in an electronic database. To evaluate outcome parameters, all patients or their relatives are contacted either personally or by phone for structured interviews. Written informed consent is obtained from every patient before inclusion in the study, and the study was approved by the local ethical committees of each participating center.

For the current study, we included all patients documented within the CAPNETZ cohort between 2002 and 2018 with (1) hospitalized CAP, (2) survival until discharge, and (3) complete follow-up data until at least 30 days after discharge. The resulting flowchart of the study cohort is depicted in Fig. 1.

Definition of the endpoint and risk factors and statistical analysis

The primary endpoint was defined as death within 30 days after discharge from the hospital.

The evaluated risk factors regarding 30-day post-discharge mortality in the study population included a variety of demographic characteristics, pre-existing chronic comorbidities, laboratory values, vital parameters, microbiological results, and treatment-related factors documented within the CAPNETZ database. Missing values are clearly stated. CRB-65 and CURB-65 scores were calculated as described before [14]; missing values for respiratory rate were set as negative criterion for score calculation.

In the exploratory data analysis, the results were presented as median with the corresponding interquartile range (IQR). Continuous variables were analyzed using a non-parametric Mann–Whitney U test for two groups of
Results

Patient characteristics and baseline risk factors

Of the 7882 patients included in our cohort study, the endpoint of death within 30 days after hospital discharge occurred in 126 (1.6%) patients. If this number is added to the 350 documented in-hospital deaths within the CAP-NETZ cohort (Fig. 1), this corresponds to 26% of all 476 deaths in the study cohort until day 30 after discharge. For 103/126 (82%) deceased patients, data on the place of death were documented in the database: 58 (56%) died during another hospitalization within 30 days after discharge from the initial CAP-related hospitalization (4 on ICU), 24 (23%) died at home, 19 (18%) in a nursing home, and 2 (2%) during rehabilitation.

Table 1 depicts the demographic characteristics, pre-existing chronic comorbidities, vital parameters, laboratory results, and score values (CURB-65, CRB-65) on hospital admission in relation to the evaluated outcome 30-day post-discharge mortality. Demographic characteristics associated with the primary outcome parameter (with \( p < 0.05 \)) in univariable analysis were higher age, lower BMI, smoking, residency in a nursing home, pre-existing long-term oxygenation therapy (LTOT), and pre-existing enteral nutrition. In univariable analysis, all except two (chronic liver disease and chronic respiratory disease) of the documented comorbidities were associated with 30-day post-discharge mortality. Regarding admission laboratory parameters, thrombocyte counts, hemoglobin, glucose, and urea were significantly associated with the endpoint. Additionally, pneumonia severity on admission as referenced by vital parameter abnormalities of respiratory rate, temperature, mental state, and the CRB-65 and CURB-65 scores were significantly associated with the outcome.

Microbiology

In 2103 patients (26.7%) of the study population, at least one pathogen was detected at hospitalization (Table 2). Two-third of infections in those 2103 patients with positive pathogen detection were caused by either Streptococcus pneumoniae (35%) and/or Mycoplasma pneumoniae (31.2%). Other pathogens detected were Enterobacteriaceae (13.2%), Legionella spp. (12.6%), Haemophilus influenzae (5.9%), Staphylococcus aureus (3.6%), influenza (5.2%), and other viruses (2.1%). Univariable analysis showed a higher rate of post-discharge mortality for infections with Enterobacteriaceae (\( p = 0.007 \)) and Staphylococcus aureus (\( p = 0.001 \)) (Table 2).

Risk factors during hospital course of CAP

A number of parameters during the hospital course follow-up are documented within the CAPNETZ-database. Their associations with the outcome are presented in Table 3. We found a significant association with the endpoint for need of various kinds of respiratory support during CAP hospitalization as well as for length of hospital stay (LOS), occurrence of a pleural effusion, need of antibiotic treatment change, and for the final diagnosis of post-obstructive pneumonia.

Multivariable regression analyses

After excluding variables with missing of more than 5% (glucose and urea), 7431/7882 of the cases (94.3%) including 110/126 patients meeting the endpoint were analyzed by multivariable regression analyses including all remaining parameters associated with post-discharge mortality after univariable analyses. Ten variables were independently associated with post-discharge mortality (Table 4).

By addition of each of the independently associated risk factors, we calculated a risk prediction score with values between 0 and 10 for 7449 patients with complete values for all 10 criteria (including 110/126 patients who met the
Table 1  Baseline characteristics of hospitalized CAP patients according to 30-day post-discharge survival status (bold, \( p < 0.05 \)) (missing values are reported as available cases/all cases)

| Post-discharge mortality ≤ 30 days | \( p \)-value |
|------------------------------------|-------------|
| Deceased                          | Not deceased |
| Total \( n \) (%)                 | 126 (1.6%)  | 7756 (98.4%) |

**Demography**

|                     | Deceased | Not deceased |
|---------------------|-----------|--------------|
| Age (years), median (IQR) | 77 (12) | 66 (25) |
| Age ≥ 65 years, \( n \) (%) | 111 (88.1) | 4215 (54.3) |
| BMI, median (IQR) \( 7721/7882 \) | 24.0 (5.13) | 25.2 (6.7) |
| Male, \( n \) (%) | 84 (66.7) | 4604 (59.4) |
| Resident in a nursing home, \( n \) (%) | 17 (13.5) | 2286 (29.5) |
| Smoker \( \text{last 12 months} \), \( n \) (%) | 7 (5.6) | 28 (22.2) |
| Chronic home ventilation, \( n \) (%) | 0 (0.0) | 415 (5.4) |
| Long-term oxygen therapy (LTOT), \( n \) (%) | 18 (14.3) | 482 (6.2) |
| Previous antibiotic therapy ≤ 4 weeks before hospital admission, \( n \) (%) | 26 (20.6) | 1834 (23.6) |
| Vaccination against influenza in previous 12 months, \( n \) (%) \( 7532/7882 \) | | 47 (43.5) | 2712 (36.5) |

**Comorbidities**

|                     | Deceased | Not deceased |
|---------------------|-----------|--------------|
| Chronic heart diseases other than chronic heart failure, \( n \) (%) | 67 (53.2) | 2813 (36.3) |
| Chronic respiratory diseases, \( n \) (%) | 44 (34.9) | 2399 (30.9) |
| Chronic heart failure, \( n \) (%) | 51 (40.5) | 1560 (20.1) |
| Diabetes mellitus, \( n \) (%) | 39 (31.0) | 1479 (19.1) |
| Chronic renal diseases, \( n \) (%) | 32 (25.4) | 781 (10.1) |
| Malignant tumor diseases, \( n \) (%) | 25 (19.8) | 768 (9.9) |
| Cerebrovascular diseases, \( n \) (%) | 30 (23.8) | 751 (9.7) |
| Other chronic neurological diseases, \( n \) (%) | 24 (19.0) | 491 (6.3) |
| Chronic liver diseases, \( n \) (%) | 2 (1.6) | 222 (2.9) |

**Vital parameters on hospital admission**

|                     | Deceased | Not deceased |
|---------------------|-----------|--------------|
| Confusion, \( n \) (%) | 25 (19.8) | 610 (7.9) |
| Body temperature ( °C), median (IQR) \( 7836/7882 \) | 37.3 (1.4) | 37.9 (1.7) |
| Respiratory rate (min\(^{-1}\)), median (IQR) \( 7406/7882 \) | 22 (8) | 20 (6) |
| Respiratory rate ≥ 30 min\(^{-1}\), \( n \) (%) | 19 (15.1) | 712 (9.2) |
| Heart rate (min\(^{-1}\)), median (IQR) \( 7827/7882 \) | 91 (24) | 90 (21) |
| Systolic BP (mmHg), median (IQR) \( 7834/7882 \) | 130 (36) | 130 (29) |
| Diastolic BP (mmHg), median (IQR) \( 7829/7882 \) | 70 (80) | 75 (15) |
| BP < 90 mmHg (syst.) or ≤ 60 mmHg (diast.), \( n \) (%) | 33 (26.2) | 1618 (20.9) |

**Laboratory results on hospital admission**

|                     | Deceased | Not deceased |
|---------------------|-----------|--------------|
| Leucocytes (Gpt/l), median (IQR) \( 7779/7882 \) | 13.33 (7.48) | 12.10 (7.00) |
| Hemoglobin (mmol/l), median (IQR) \( 7730/7882 \) | 7.88 (1.51) | 8.26 (1.43) |
| Thrombocytes (Gpt/l), median (IQR) \( 7646/7882 \) | 275 (156) | 237 (126) |
| C-reactive protein (mg/l), median (IQR) \( 7719/7882 \) | 88 (163.6) | 108 (184.1) |
| Sodium (mmol/l), median (IQR) \( 7744/7882 \) | 137 (6) | 137 (5) |
| Urea (mmol/l), median (IQR) \( 6945/7882 \) | 7.79 (6.66) | 5.70 (4.50) |
| Urea > 7 mmol/l, \( n \) (%) \( 6945/7882 \) | 60 (54.1) | 2426 (35.5) |
| Glucose (mmol/l), median (IQR) \( 7295/7882 \) | 7.39 (3.02) | 6.78 (2.62) |

**Scores**

|                     | Deceased | Not deceased |
|---------------------|-----------|--------------|
| CURB-65-Index, median (IQR) \( 6945/7882 \) | 2 (2) | 1 (2) |
| 0, \( n \) (%) | 4 (3.6) | 1918 (28.1) |
| 1, \( n \) (%) | 29 (26.1) | 2169 (31.7) |
| 2, \( n \) (%) | 43 (38.7) | 1821 (26.6) |
| 3, \( n \) (%) | 27 (24.3) | 776 (11.4) |
primary endpoint). Frequency and proportion of 30-day post-discharge mortality according to defined score-values are shown in the supplementary e-Fig. 1. The score was significantly associated with post-discharge survival probability as demonstrated by Kaplan–Meier analysis (\( p < 0.001 \), Fig. 2). The score showed an area under the curve (AUC) of 0.831 (95% CI 0.822–0.839, \( p \)-value < 0.001) for predicting 30-day post-discharge mortality. The suggested optimal cut-off according to Youden Index was \( >3 \) score points with a sensitivity of 90.0% (95% CI 82.8–94.9), a specificity of 60.9% (95% CI 59.8–62.0), a positive LR of 2.30 (2.1–2.5), and a negative LR of 0.16 (0.09–0.3). Detailed diagnostic properties for each cut-off of the score are depicted in the supplementary e-Table 1; the distribution of score values among the study population is shown in supplementary e-Fig. 2.

### Table 1 (continued)

| CRB-65-Index, median (IQR) | Deceased | Not deceased | \( p \)-value |
|---------------------------|----------|--------------|--------------|
| 4, \( n \) (%)            | 5 (4.5)  | 141 (2.1)    |              |
| 5, \( n \) (%)            | 3 (2.7)  | 9 (0.1)      |              |
| CRB-65-Index, median (IQR)\( 0, \( n \) (%) | 6 (4.8)  | 2542 (32.8)  |              |
| CRB-65-Index, median (IQR)\( 1, \( n \) (%) | 65 (51.6)  | 3533 (45.6)  |              |
| CRB-65-Index, median (IQR)\( 2, \( n \) (%) | 45 (35.7)  | 1437 (18.5)  |              |
| CRB-65-Index, median (IQR)\( 3, \( n \) (%) | 7 (5.6)  | 228 (2.9)    |              |
| CRB-65-Index, median (IQR)\( 4, \( n \) (%) | 3 (2.4)  | 16 (0.2)     |              |

### Table 2 Association of microbiological etiology with 30-day post-discharge mortality (more than one pathogen per patient possible) (bold \( p < 0.05 \))

| Post-discharge mortality \( \leq 30 \) days | Deceased | Not deceased | \( p \)-value |
|--------------------------------------------|----------|--------------|--------------|
| No pathogen identified                     | 88       | 5691         |              |
| Detection of pathogen, \( n \) (%)         | 38 (30.2)| 2065 (26.6)  | 0.374        |
| *Streptococcus pneumoniae, n (%)*          | 7 (18.4) | 728 (35.3)   | 0.142        |
| *Mycoplasma pneumoniae, n (%)*              | 11 (28.9)| 645 (31.2)   | 0.867        |
| *Enterobacteriaceae, n (%)*                 | 10 (26.3)| 267 (12.9)   | 0.007        |
| *Legionella spp., n (%)*                    | 7 (18.4) | 258 (12.5)   | 0.169        |
| *Haemophilus influenzae, n (%)*             | 2 (5.3)  | 123 (6.0)    | 0.999        |
| *Influenza, n (%)*                          | 2 (5.3)  | 108 (5.2)    | 0.853        |
| *Staphylococcus aureus, n (%)*              | 5 (13.2) | 71 (3.4)     | 0.001        |
| Other viruses, \( n \) (%)                  | 1 (2.6)  | 44 (2.1)     | 0.738        |

### Table 3 Characteristics during hospitalization of CAP-patients according to 30-day post-discharge survival status (bold \( p < 0.05 \))

| Post-discharge mortality \( \leq 30 \) days | Deceased | Not deceased | \( p \)-value |
|--------------------------------------------|----------|--------------|--------------|
| Length of hospitalization (LOS) in days, median (IQR) | 14 (10)  | 10 (6)       | < 0.001      |
| Oxygen therapy anytime, \( n \) (%)         | 114 (90.5)| 5370 (69.2)  | < 0.001      |
| New onset oxygen therapy during pneumonia, \( n \) (%) | 96 (76.2) | 4888 (63.0)  | 0.002        |
| Oxygen therapy in follow up but not on admission to hospital, \( n \) (%) | 16 (12.7) | 514 (6.6)    | 0.007        |
| New onset mechanical ventilation (non invasive or invasive) because of CAP, \( n \) (%) | 18 (14.3) | 548 (7.1)    | 0.002        |
| ICU admission, \( n \) (%)                   | 7 (5.6)  | 354 (4.6)    | 0.597        |
| Treatment with vasopressors, \( n \) (%)     | 2 (1.6)  | 55 (0.7)     | 0.248        |
| Post-obstructive pneumonia, \( n \) (%)      | 12 (9.5) | 110 (1.4)    | < 0.001      |
| Pleural effusion anytime, \( n \) (%)        | 38 (30.2)| 1520 (19.6)  | 0.003        |
| Pleural effusion developing during hospitalization, \( n \) (%) | 9 (7.1)  | 213 (2.7)    | 0.003        |
| Change of antibiotic treatment during hospitalization, \( n \) (%) | 60 (47.6) | 3015 (38.9)  | 0.046        |
Discussion

To understand the relationship between CAP and early post-discharge mortality and to identify a risk group to target intensified post-discharge follow-up, we analyzed data from the large-scale well-characterized prospective multi-national CAPNETZ study. The main findings of our study are that (1) early post-discharge mortality accounts for 26% of all deaths occurring until day 30 after hospital discharge in hospitalized CAP, and (2) several risk factors were associated with early post-discharge mortality including demographic factors, comorbidities, admission laboratory and vital parameters and factors related to the hospital course of CAP.

In our study cohort, early post-discharge mortality of 1.6% was rather low compared to other recent cohorts which showed early post-discharge mortality rates between 3 and 8% [4, 6–10] and even up to 11% in a recent study from Turkey [15]. One plausible explanation might be that most studies included retrospective cohorts or population-based evaluations, whereas in CAPNETZ patients are prospectively recruited after a requested informed consent, which might introduce selection bias towards younger and healthier patients. This additionally is illustrated by the rather low hospital mortality rate within our cohort of 3.9% when compared to population based data of hospitalized CAP in Germany with hospital mortality rates of
12–17%, and is further reflected by the lower median age and lower rates of chronic comorbidities when compared to the population based cohorts, and the high rate of *Mycoplasma pneumoniae* and the low rate of influenza as CAP etiology [4, 16]. Thus, the presented data might predominantly apply to younger and healthier cohorts but should be prospectively validated in less pre-selected population-based cohorts.

However, the CAPNETZ cohort carries the advantages of a well-characterized prospective cohort with high data quality, and the relative impact of 30-day post-discharge mortality in CAPNETZ with 126 of 476 (26%) of all deaths until day 30 after discharge remains substantial.

We found several variables associated with post-discharge mortality which could be grouped into (1) demographic factors, (2) pre-existing comorbidities, (3) admission laboratory and vital parameters suggesting more severe CAP, (4) CAP-causing pathogens, and (5) other factors associated with CAP severity and treatment course. Ten risk factors both patient-related and CAP-related were identified as independently associated with early survival status after multivariable analysis. Patient-related risk factors included age, low BMI and the presence of diabetes, chronic neurological disease other than cerebrovascular diseases, and/or chronic renal diseases. Parameters correlating with severity of pneumonia included LOS, higher admission platelet counts, lower admission body temperature, the need for oxygen therapy during hospitalization, and post-obstructive pneumonia. By addition of those predictors, we calculated a score which—if validated by external cohorts—might help targeting intensified post-discharge follow-up visits in patients at risk.

To our knowledge, there are very few studies evaluating risk factors for early post-discharge mortality. One study examined 90-day post-discharge mortality in 1117 adult CAP-patients and found pre-illness functional status, comorbidities evaluated by Charlson index and CAP severity associated with that endpoint [6]. Another recent Turkish monocenter study found older age, renal comorbidity, and laboratory markers of CAP severity associated with 30-day post-discharge mortality [15]. Most other studies reporting post-discharge mortality in CAP were not designed to evaluate risk factors but to compare factors associated with in-versus post-hospital mortality [7], to evaluate prediction by clinical stability criteria [9] or to measure associations with interventions on a population based level [5, 10]. Additionally, studies on causes of readmission within 30 days after discharge identified patients with coexisting chronic comorbidities, poor functional state, and higher leucocytes or lower albumin concentrations at discharge to be readmitted more frequently [17–20].

The presence of post-obstructive CAP was the strongest single risk factor for poor outcome after discharge: Compared to 1.4% of the control group, 9.5% of the deceased cohort had post-obstructive CAP. This condition is almost always associated with a malignant neoplasm of the lung, resulting in bronchus displacement and consequent pulmonary infiltrate [21]. Post-obstructive CAP has also been shown to be associated with increased 30-day in-hospital mortality [21, 22].
Surprisingly, preexisting cardiac diseases (chronic heart failure and other chronic heart diseases) were associated with post-discharge mortality after univariable, but not after multivariable analysis in our cohort. In a recent review article, Musher et al. evaluated and summarized studies on temporal association of myocardial infarction with acute pulmonary infections [23]. Not only is the risk of myocardial infarction increased in the post-infection period, but such risk elevation persisted in the long term up to ten years after the infection. However, the absence of this association in our cohort does not exclude acute cardiovascular complications as relevant contributor to post-discharge mortality, as we are not able to provide data on acute cardiovascular complications during CAP hospitalization. Additionally our data might not apply to population-based CAP cohorts with higher age and a higher frequency of chronic comorbidities. Unfortunately, there also is no data available on the cause of post-discharge death in our study. In that context, the finding of higher thrombocyte values to be associated with post-discharge mortality is of interest. Both thrombocytosis and thrombocytopenia are associated with increased severity of pneumonia and poor outcome [24]. Activation of platelets in the course of an infectious disease can lead to increased formation of thrombi and thus may trigger cardiovascular complications such as myocardial infarction. Platelet activation markers were shown to be independent predictors for myocardial infarction as an early complication in CAP patients [25]. Another laboratory value that could be of prognostic value for early post-discharge death is troponin. Vestjens et al. showed that elevated high-sensitivity cardiac troponin T levels detected on admission in patients hospitalized with CAP has been associated with short- and long-term mortality [26]. Unfortunately, we have no data on this marker in the database.

The findings of our study carry potential implications for CAP management. Whereas in cases with data on the place of post-discharge death in our cohort 18% occurred in a nursing home, where multimorbidity and treatment restrictions might play a role, 56% of deceased patients were re-admitted to a hospital before their death, suggesting an unexpected post-hospitalization course. There is an urgent need to expand our understanding of and attitude towards the management of CAP beyond acute care, and to consider and evaluate post-discharge interventions in patients at risk. If our identified risk factors will be replicated by independent cohorts, they might enable targeted post-discharge interventions in high-risk patients like intensified follow-up visits and careful monitoring of organ function, regarding pre-existing comorbidities as well as late complications of CAP, with the aim to improve early post-discharge prognosis. A potential role of interventions to improve post-discharge prognosis after CAP has been suggested by a recent US cohort study by demonstrating an inverse association between the number of in-hospital physical and occupational therapist visits during acute care of CAP and 30-day post-discharge readmission or death rate, especially in patients with mobility limitations discharged into the community [10].

Even though the multi-national CAPNETZ study cohort is well characterized, important limitations of the study should be considered. In comparison to population-based studies, early post-discharge mortality in the prospectively recruited CAPNETZ study cohort was rather low, which might limit representativeness of our data. In addition, we missed follow-up data in 8.8% of discharged cases, which might include also deceased cases. Furthermore, laboratory values and vital signs used in the analysis were acquired at hospital admission, but no data are available on the corresponding parameters evaluated before discharge. Potential additional risk factors like data on oxygenation or acute cardiac complications during CAP could not be analyzed due to missing data. The clinical stability criteria have an established role in deciding whether a patient can be evaluated for hospital discharge [9, 11, 12], but data on these criteria were not available in our cohort. Furthermore, data on causes of death were unavailable. Finally, our proposed score to predict early post-discharge mortality needs validation within independent cohorts.

**Conclusion**

In the multi-national prospective CAPNETZ study cohort, we found that early post-discharge deaths accounted for 26% of all deaths occurring until day 30 after discharge, and we identified several patient- and CAP-related risk factors associated with early post-discharge mortality. Additional studies are necessary to replicate our findings in independent cohorts and to identify and evaluate possible interventions to improve early post-discharge prognosis in CAP. Meanwhile, intensified post-discharge follow-up with close monitoring of preexisting comorbidities and CAP complications might be considered especially in elderly, multimorbid patients and those with severe CAP after hospital discharge.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s10096-022-04416-5.

**Acknowledgements** CAPNETZ is a multidisciplinary approach to better understand and treat patients with community-acquired pneumonia. The network has only been made possible by the contribution of many investigators. We are especially indebted to the work of the investigators in the local clinical centers (LCC) who established and cooperated within the network.

Members of the CAPNETZ study group are as follows: M. Dreher, C. Cornelissen (Medical Clinic I, University Clinic RWTH Aachen); W. Knüppel (Clinic for Internal Medicine, Hospital Bad Arolsen); D. Stolz;
(Clinic for Pneumology, Uni-Spital Basel, Switzerland); N. Suttorp, P. Creutz, M. Witzenrath, A. Mikolajewska, A. le Claire, M. Benzke (Department of Infectious Disease and Respiratory Medicine, Charité-University Medicine, Berlin); T. Bauer, D. Krieger (HELIOS Klinikum Emil von Behring, Berlin); M. Prediger, S. Schmager (III. Medical Clinic, Carl-Thiem-Klinikum Cottbus); M. Kolditz, B. Schulte-Hubbert, S. Langner (Medical Department, Division of Pulmonology, University Hospital Dresden); G. Rohde (Medical Clinic I – Pneumology/Allergology, University Hospital Frankfurt); O. Degen, A. Hüfner (Outpatient Center, University Hospital Hamburg-Eppendorf); C. Hoffmann (ICH Study Center, Hamburg); T. Welte, J. Freise (Department of Respiratory Medicine, Hannover Medical School, Hannover); G. Barten-Neiner, M. Nawrocki, I. Fuge, J. Naim, W. Krönner (CAPNETZ Office, Hannover); T. Illig, N. Klopp (Hannover University Biobank); C. Kroegel, A. Moeser (Department of Pneumology & Allergy/Immunology, University Hospital Jena); M. Pleiz, B. Schleenvoigt, C. Bahrs (Institute of Infectious Diseases and Infection Control (IIMK), University Hospital Jena); D. Drömann, P. Parschke, K. Franzen (Med. Clinic III, Pulmology, University Hospital Schleswig-Holstein, Lübeck); J. Rupp, N. Käding (Department of Infectiology and Microbiology, University Hospital Schleswig-Holstein, Lübeck); M. Wouters, K. Walraven, D. Braeken (Department of Respiratory Medicine, Maastricht University Medical Center-MUMC+, Maastricht, The Netherlands); C. Spinner (Clinic for Pneumology and General Internal Medicine, Rechts der Isar Hospital, Munich); H. Buschmann, A. Zaruchas (Medical Clinic-Pneumology, Brüderkrankenhaus St. Josef, Paderborn); T. Schaberg, I. Hering (Center of Pneumology, Diakonie-Hospital Rotenburg); W. Albrich, F. Waldeck, F. Rassoul, S. Baldesberger (Department of Infectiology and Hospital Hygiene, Kantonsspital St. Gallen, Switzerland); M. Panning (University Medical Center Freiburg, Institute of Virology); M. Wallner (2mt Software, Ulm); and all study nurses.

Author contribution All authors made substantial contribution to the study design, data collection, analysis or interpretation, drafting the article, and revising it critically for important intellectual content. All authors approved the final version to be submitted. VG, MWP, GR, JR, MW, GB, and MK designed the study; VG and MK drafted the article; VG and MK performed the statistical analysis. VG, MWP, GR, JR, MW, and GB contributed to the critical revisions, and final approval of the article. MK is the guarantor of the content of the manuscript including the data and analysis.

Funding Open Access funding enabled and organized by Projekt DEAL. CAPNETZ was founded by a German Federal Ministry of Education and Research grant (01KI07145) 2001–2011. MWP is partly supported by a grant of the Federal Ministry of Education and Research KliFo 2.0 (grant number 01KI1501).

Data availability The data are stored electronically within the CAPNETZ database and are available from CAPNETZ on reasonable request.

Declarations Ethics approval Written informed consent is obtained from every patient before inclusion in the study, and the study was approved by the local ethical committees of each participating center.

Consent to participate Not applicable.

Consent for publication Not applicable.

Conflict of interest Dr. Pleiz reports grants from Pfizer and consulting fees or honoraria for lectures or advisory boards from Pfizer, MSD, Brahms, Novartis, and Chiesi, all outside the submitted work. Dr. Rohde reports consulting fees or honoraria for lectures or advisory boards from Astra Zeneca, Berlin Chemie, BMS, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Solvay, Takeda, Novartis, Pfizer, and Vertex, all outside the submitted work. Dr. Kolditz reports grants from Pfizer and consulting fees or honoraria for lectures or advisory boards from Berlin Chemie, Böhrringer, MSD, Astra Zeneca, Biotest, Novartis, Pfizer, GSK, Gilead, and Sanofi, all outside the submitted work. Dr. Witzenrath reports grants from Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Marie Curie Foundation, Capnetz Stiftung, Noxxon, Panthera, Vaxxilon, Bayer Health Care, Biotest; and consulting fees or honoraria from Noxxon, Panthera, Silence Therapeutics, Vaxxilon, Aptarion, Glaxo Smith Kline, Sinoxa, Biotest, Astra Zeneca, Berlin Chemie, Chiesi, Novartis, Teva, Actelion, Boehringer Ingelheim, and Bayer Health Care, all outside the submitted work.

Ms. Glöckner and Barten-Neiner declare no conflict of interests relevant to the content of the article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Kolditz M, Braeken D, Ewig S, Rohde G (2016) Severity assessment and the immediate and long-term prognosis in community-acquired pneumonia. Semin Respir Crit Care Med 37(6):886–896
2. Holter JC, Ueland T, Jenum PA, Muller F, Brunborg C, Froland SS, Aukrust P, Husebye E, Heggelund L (2016) Risk factors for long-term mortality after hospitalization for community-acquired pneumonia: a 5-year prospective follow-up study. PLoS One 11(2):e0148741
3. Bruns AH, Oosterheert JJ, Cucchiollo MC, El MR, Groenewold RH, Prins JM, Hoepelman AI (2011) Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia as compared with the general Dutch population. Clin Microbiol Infect 17(5):763–768
4. Kolditz M, Tesch F, Mocke L, Hoffken G, Ewig S, Schmitt J (2016) Burden and risk factors of ambulatory or hospitalized CAP: a population based cohort study. Respir Med 121:32–38
5. Wadhera RK, Joynt Maddox KE, Wasfy JH, Haneuse S, Shen C, Yeh RW (2018) Association of the hospital readmissions reduction program with mortality among medicare beneficiaries hospitalized for heart failure, acute myocardial infarction, and pneumonia. JAMA 320(24):2542–2552
6. Capelastegui A, Espana PP, Quintana JM, Bilbao A, Menendez R, Zalacain R, Torres A (2009) Development of a prognostic index for 90-day mortality in patients discharged after...
admission to hospital for community-acquired pneumonia. Thorax 64(6):496–501
7. Metersky ML, Waterer G, Nsa W, Bratzler DW (2012) Predictors of in-hospital vs postdischarge mortality in pneumonia. Chest 142(2):476–481
8. Lindenaener PK, Normand SL, Drye EE, Lin Z, Goodrich K, Desai MM, Bratzler DW, O’Donnell WJ, Metersky ML, Krumholz HM (2011) Development, validation, and results of a measure of 30-day readmission following hospitalization for pneumonia. J Hosp Med 6(3):142–150
9. Albicerti S, Zanaboni AM, Wiemken T, Nahas A, Uppatal S, Molkacchi LC, Peyrani P, Blasi F, Ramirez J (2013) Criteria for clinical stability in hospitalised patients with community-acquired pneumonia. Eur Respir J 42(3):742–749
10. Freburger JK, Chou A, Euloth T, Matcho B (2020) Variation in acute care rehabilitation and 30-day hospital readmission or mortality in adult patients with pneumonia. JAMA Netw Open 3(9):e2012979
11. Ewig S, Kolditz M, Pletz M, Altiner A, Albrich W, Dromann D, Flick H, Gatermann S, Kruger S, Nehls W, Panning M, Rademacher J, Rohde G, Rupp J, Schaaf B, Heppner HJ, Krause R, Ott S, Welte T, Witzenrath M (2021) Management of adult community-acquired pneumonia and prevention - update 2021 - guideline of the German Respiratory Society (DGR), the Paul-Ehrlich-Society for Chemotherapy (PEG), the German Society for Infectious Diseases (DIGI), the German Society of Medical Intensive Care and Emergency Medicine (DGIN), the German Biological Society (DG), the Competence Network CAPNETZ, the German College of General Practitioners and Family Physicians (DEGAM), the German Society for Geriatric Medicine (DGGM), the German Palliative Society (DG), the Austrian Society of Pneumology (OSP), the Austrian Society for Infectious and Tropical Diseases (OOGI), the Swiss Respiratory Society (SGS) and the Swiss Society for Infectious Diseases Society (SSI). Pneumologie 75(9):665–729
12. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Coth- ers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG (2019) Diagnosis and treatment of adults with community-acquired pneu-
13. Welte T, Sutorp N, Marre R (2004) CAPNETZ—community-acquired pneumonia competence network. Infection 32(4):234–238
14. Lim WS, van der Erden ML, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT (2003) Defining community acquired pneumonia severity on presentation to hospital: an inter-
national derivation and validation study. Thorax 58(5):377–382
15. Çınarka H, Yurt S, Tanrıverdi E, Eğilir Chousein E, Turan D, Yıldırım Z, Çörtlük M, Çetinkaya E (2020) Post discharge short term mortality in hospitalized patients with community-acquired pneumonia. Haydarpasa Numune Med J 60(4):6
16. Kesselmeier M, Pletz MW, Blankenstein AL, Scherag A, Bauer T, Ewig S, Kolditz M (2021) Validation of the qSOFA score compared to the CRB-65 score for risk prediction in community-acquired pneumonia. Clin Microbiol Infect 27(9):1345 e1-1345 e6
17. Chakrabarti B, Lane S, Jenks T, Higgins J, Kanwar E, Allen M, Wotton D (2021) Predictors of 30-day readmission following hospitalisation with community-acquired pneumonia. BMJ Open Respilir Res 8(1). https://doi.org/10.1136/bmjresp-2021-000883
18. Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ (2008) Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis 46(4):550–556
19. Toledo D, Soldevila N, Torner N, Perez-Lozano MI, Espejo E, Navarro G, Egurmola M, Dominguez A, F.I.S.P.I.W.G. (2018) On-behalf of the Project (2018) Factors associated with 30-day readmission after hospitalisation for community-acquired pneumonia in older patients: a cross-sectional study in seven Spanish regions. BMJ Open 8(3):e020243
20. Petersen PT, Egeland GB, Jensen AV, Andersen SB, Pedersen MF, Rohde G, Ravn P (2018) Associations between biomarkers at discharge and co-morbidities and risk of readmission after community-acquired pneumonia: a retrospective cohort study. Eur J Clin Microbiol Infect Dis 37(6):1103–1111
21. Rolston KVI, Neshel L (2018) Post-obstructive pneumonia in patients with cancer: a review. Infect Dis Ther 7(1):29–38
22. Abers MS, Sandvall BP, Sampath R, Zuno C, Uy N, Yu VL, Stager CE, Musler DM (2016) Postobstructive pneumonia: an underdescribed syndrome. Clin Infect Dis 62(8):975–981
23. Musler DM, Abers MS, Corrales-Medina VF (2019) Acute infec-
tion and myocardial infarction. N Engl J Med 380(2):171–176
24. Prina E, Ferrer M, Ranzani OT, Polverino E, Cilloniz C, Moreno E, Menza J, Montull B, Menendez R, Cosentini R, Torres A (2013) Thrombocytosis is a marker of poor outcome in community-acquired pneumonia. Chest 143(3):767–775
25. Cangemi R, Casciaro M, Rossi E, Calvieri C, Bucci T, Calabrese CM, Taliani G, Falcone M, Palange P, Bertazzoni G, Farcomeni A, Greco S, Pignatelli P, Violi F, S.S. Group, S.S. Group (2014) Platelet activation is associated with myocardial infarction in patients with pneumonia. J Am Coll Cardiol 64(18):1917–1925
26. Vestjens SMT, Spoorenberg SMC, Rijkers GT, Cruiters JC, Ten Berg JM, Noordzij PG, Van de Garde EMW, Bos WJW, G. Ovid-

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.